PRODUCT CODE: EM1902-34

FOXA1 Mouse Monoclonal Antibody [A2E8] (EM1902-34)

Applications

  • WB

  • FC

REACTIVITY

  • Human

Western blot analysis of FOXA1 on MCF-7 cell lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-34, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Western blot analysis of FOXA1 on MCF-7 cell lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-34, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Flow cytometric analysis of FOXA1 was done on MCF-7 cells. The cells were fixed, permeabilized and stained with the primary antibody (EM1902-34, 1/50) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Mouse IgG Secondary antibody at 1/1000 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; black).
Western blot analysis of FOXA1 on MCF-7 cell lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-34, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.

Applications

  • WB

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

FOXA1 Mouse Monoclonal Antibody [A2E8] (EM1902-34)

Immunogen

Synthetic peptide within n-terminal human foxa1.

Host

Mouse

Positive Control

MCF-7 cell lysates, MCF-7.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

A2E8

PROPERTIES

Form

Liquid

Storage Condition

Store at +4Á¾ after thawing. Aliquot store at -20Á¾. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein G affinity purified.

MOLECULAR WEIGHT

Predicted band size: 49 kDa.

Isotype

IgG1

APPLICATION DILUTION

  • WB

  • 1:500-1:1,000

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

FOXA1

SYNONYMS

forkhead box A1 antibody; Forkhead box protein A1 antibody; FOX A1 antibody; FOXA1 antibody; FOXA1_HUMAN antibody; hepatocyte nuclear factor 3 alpha antibody; Hepatocyte nuclear factor 3-alpha antibody; HNF 3A antibody; HNF-3-alpha antibody; HNF-3A antibody; HNF3A antibody; MGC33105 antibody; TCF 3A antibody; TCF-3A antibody; TCF3A antibody; Transcription factor 3A antibody

SUBCELLULAR LOCATION

Nucleus.

FUNCTION

Forkhead box protein A1 (FOXA1), also known as hepatocyte nuclear factor 3-alpha (HNF-3A), is a protein that in humans is encoded by the FOXA1 gene. FOXA1 is a member of the forkhead class of DNA-binding proteins. These hepatocyte nuclear factors are transcriptional activators for liver-specific transcripts such as albumin and transthyretin, and they also interact with chromatin as a pioneer factor. Similar family members in mice have roles in the regulation of metabolism and in the differentiation of the pancreas and liver. FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 acts as a pioneer factor for ERa in ERα+ breast cancer, and its expression might identify ERα+ cancers that undergo rapid reprogramming of ERa signaling that is associated with poor outcomes and treatment resistance. Conversely, in ERα− breast cancer FOXA1 is highly correlated with low-grade morphology and improved disease free survival. FOXA1 is a downstream target of GATA3 in the mammary gland. Expression in ERα− cancers may identify a subset of tumors that is responsive to other endocrine therapies such as androgen receptor antagonist treatment.